8月15日晚间， 白云山 （600332.SH；00874.HK）发布2025年中期业绩报告，在医药行业整体承压的大环境下，其营收虽有增长，利润却出现下滑，研发费用大幅缩减，旗下板块业绩分化明显，一系列问题凸显，未来发展之路充满挑战。增收不增利，利润下滑隐忧浮现数据显示，白云山上半年实现营业收入418.35亿元，同比增长1.93%，看似实现了一定程度的增长。然而，归母净利润为25.16亿元，同比...
Source Link8月15日晚间， 白云山 （600332.SH；00874.HK）发布2025年中期业绩报告，在医药行业整体承压的大环境下，其营收虽有增长，利润却出现下滑，研发费用大幅缩减，旗下板块业绩分化明显，一系列问题凸显，未来发展之路充满挑战。增收不增利，利润下滑隐忧浮现数据显示，白云山上半年实现营业收入418.35亿元，同比增长1.93%，看似实现了一定程度的增长。然而，归母净利润为25.16亿元，同比...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.